DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Prescription writing (Cont.):
date in, 1881–1882
drug product choice and amount in,
1882
errors in, 1883
history of, 1879
mechanics of, 1879–1883
patient information in, 1881
refills in, 1881–1882
signa in, 1879
subscription in, 1879
Pressure-natriuresis curve, 729, 729f,
730
Pressurized metered-dose inhalers,
1035
Preterm labor
complications of, 1847
definition of, 1847
established, tocolytic therapy for,
1848
etiology of, 1847–1848
prevention of, 1848
risk factors for, 1848
scope of problem, 1847–1848
PREVACID NAPRAPAC, 988
PREVEN (levonorgestrel and ethinyl
estradiol), 1837
Prevertebral ganglia, 174
Pricing, of drugs, 11
Prilocaine, 573–574
Primaquine, 1409–1410
Primaquine phosphate, 1392t
Primary active transport, 94, 94f
Primary bile salt malabsorption, 102t
PRINIVIL (lisinopril), 733, 797
Probenecid
absorption of, 999
adverse effects and side effects of,
999
distribution of, 999
elimination, 999
mechanism of action of, 999
and penicillin, combination therapy
with, 999
pharmacokinetics of, 999
structure of, 999
therapeutic uses of, 999
Probiotics, 1337, 1360
Procainamide
adverse effects of, 842–843
antiarrhythmic use of, 824t, 836t,
842–843
arrhythmias caused by, 821t
contraindications to, 833t
dosage of, 836t
electrophysiological actions of, 829t
Procainamide (Cont.):
metabolism of, 128t
pharmacokinetics of, 836t, 843,
1877t
pharmacological properties of, 842
polymorphisms and response to,
159t
side effects of, 138t
structure of, 842
Procaine, 574
PROCAN SR (procainamide), 842
Procarbazine, 1668t–1670t
PROCARDIA (nifedipine), 762t, 1848
PROCARDIA XL (nifedipine), 1847
Procaterol, 292f, 293
PROCHIEVE (micronized progesterone),
1844
Prochlorperazine, as antinausea agent,
in cancer chemotherapy,
1344t
Product liability, 13
Profitability, 11
Progesterone, for prevention of
preterm labor, 1848
Progesterone, ABC transporters and,
105t
Progestin-only contraceptives, 1186
mechanism of action, 1186–1187
Progestins, 1668t–1670t
absorption, fate, and excretion of,
1183
biosynthesis of, 1181
in cancer chemotherapy, 1755–1756
central nervous system and, 1182
chemistry of, 1181
for endometriosis, 1840
history of, 1163
for induction of sexual maturat6ion,
1838
mammary glands and, 1182
mechanism of action of, 1182–1183
for menopausal symptoms, 1838
administration routes, 1839–1840
brand names, 1839t
metabolic effects of, 1182
oral
brand names, 1839t
formulations, 1839t
in oral contraceptives, 1833,
1835t–1836t
physiological and pharmacological
actions of, 1182
secretion of, 1181
PROGRAF (tacrolimus), 1822
Progressive familial intrahepatic
cholestasis type 2, 104t
Progressive familial intrahepatic
cholestasis type 3, 104t
Progressive multifocal
leukoencephalopathy (PML)
efalizumab and, 1825
mycophenolate mofetil and, 1823
Proguanil, 1400–1402
polymorphisms and response to,
159t
Proischemia, calcium channel
antagonists and, 766
Prokinetic agents, 1325–1328,
1334–1335
Prolactin, 1106–1117, 1106t
excess of, 1111
impaired production of, 1111–1112
molecular bases of, 1109–1110
opioids and, 495
pathophysiology of, 1111–1112
physiological effects of, 1110–1111
physiology of, 1106–1111
PROLEUKIN (aldesleukin), 1749
Prolylcarboxypeptidase, 929
Promethazine, 921t, 924
local anesthetic effects of, 920
pharmacokinetics of, 1816t, 1877t
structure of, 919f
therapeutic uses of, 923
for motion sickness, 920
and vasopressin secretion, 704
PROMETRIUM (micronized
progesterone), 1839t
Promotion, of drugs, 12–13
Pronethalol, 778
Propafenone
adverse effects of, 843
antiarrhythmic use of, 824t, 828,
843
arrhythmias caused by, 821t
contraindications to, 833t
dosage of, 836t
drug interactions with, 839, 844
electrophysiological actions of, 829t
pharmacokinetics of, 836t, 843
polymorphisms and response to,
159t
structure of, 843
Propamide isethionate, for ophthalmic
use, 1783
PROPECIA (finasteride), 1829
Property, intellectual, 12
Prophylactic antimalarial therapy,
1411–1415
Prophylactic antimicrobial therapy,
1373–1375
Prophylactic sulfonamides, 1467
2063
INDEX